The Federal Commission for the Protection against Sanitary Risks (Cofepris) reported on the authorization of 20 new medicinesof which five are innovative and 15 are generic, as well as 103 medical devices.
In the second Fortnightly Report on Therapeutic Expansion, the regulatory body pointed out that it is about guaranteeing the balance between innovative medicines and generics, promoting greater access at lower costs.
As we have mentioned in other informative notes of The Truth NewsCofepris issues sanitary records to those health supplies that verify compliance with standards through scientific and technical studies.
What are the medical supplies authorized by Cofepris?
Cofepris presented the second Fortnightly Report on Therapeutic Expansion
Regarding clinical trials, Cofepris reported that 10 were authorized to evaluate new therapeutic alternatives for diseases such as hepatitis B, breast cancer, lupus nephritis, inflammatory bowel disease, and atopic dermatitis.
On the subject, the head of Cofepris, Alejandro Svarch Pérez, confirmed that Mexico has an authority that reliably and effectively complies with the protection against health risks, highlighting its operational technical and regulatory policy capacity.
According to the list of authorized medicines, these cover 11 different therapeutic groups:
- 1. Analgesics: paracetamol/tramadol; etoricoxib/tramadol
- 2. Anesthesiology: ropofol
- 3. Endocrinology: desmopressin; metformin/vidagliptin (2); teriparatide
- 4. Gastroenterology: esomeprazole
- 5. Hematology:tranexamic acid
- 6. Infectious diseases: daptomycin
- 7. Neurology: carbidopa/levodopa; levetiracetam
- 8. Oncology: etoposide; encorafenib; vinblastine; tofacitinib
- 9. Psychiatry: amfebutamone; methylphenidate
- 10. Rheumatology: hydroxychloroquine
- 11. Emergencies: norepinephrine
YOU MAY BE INTERESTED: Cofepris approves a drug to address obesity problems in Mexico
Regarding the issue of the 103 sanitary registries for medical devices, Cofepris reported that 70 percent is oriented toward the diagnosis of diseases, 21 percent is for treatment, and 9 percent corresponds to supplies for medical care in general.
Among the approved products, a new alternative for the detection of acute myocardial infarction stands out, with greater opportunity than the usual options; In addition, it makes it possible to detect proteins that occur in the early stages of this type of disease with a high specification, as well as a device that helps manage complications caused by valve replacement surgeries.
Follow us on Google news, Facebook and Twitter to keep you informed.
